Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani et al. · The Lancet · 2021 · 1.5K citations

Hematological Malignancy, Cell Therapy, Immunotherapy +11

Teclistamab in Relapsed or Refractory Multiple Myeloma

Philippe Moreau, Alfred L. Garfall, Niels W.C.J. van de Donk et al. · New England Journal of Medicine · 2022 · 990 citations · Full text

Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 ⁺ and CD4 ⁺ CD19-specific chimeric antigen receptor–modified T cells

Cameron J. Turtle, Laïla‐Aïcha Hanafi, Carolina Berger et al. · Science Translational Medicine · 2016 · 989 citations

Immunology, Pathology, Cd4 T Cell Responses +19

Decade-long leukaemia remissions with persistence of CD4+ CAR T cells

J. Joseph Melenhorst, Gregory M. Chen, Meng Wang et al. · Nature · 2022 · 851 citations · Full text

Hematological Malignancy, Decade-long Leukaemia Remissions, Malignant Blood Disorder +8

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

Joseph A. Fraietta, Christopher L. Nobles, Morgan A. Sammons et al. · Nature · 2018 · 829 citations · Full text

Cd19-targeted T Cells, Cancer Immunosurveillance, Immunology +8